Status:

COMPLETED

Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stages I, II, or III Cervical Cancer

Lead Sponsor:

University of California, Irvine

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Cervical Cancer

Psychosocial Effects of Cancer and Its Treatment

Eligibility:

FEMALE

18-120 years

Phase:

NA

Brief Summary

RATIONALE: Telephone counseling after treatment may reduce stress and improve the well-being and quality of life of patients who have cervical cancer. Changes in quality of life may be related to chan...

Detailed Description

OBJECTIVES: * Compare quality of life (QOL) at baseline and changes in QOL, immune response, and neuroendocrine parameters over time in patients who have completed treatment for stage I-III cervical ...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA
  • Disease Characteristics:
  • Diagnosis of cervical cancer between the past 3-15 months
  • Stage I-III disease
  • Completed therapy for cervical cancer ≥ 1 month ago
  • Not receiving ongoing treatment
  • More than 4 weeks since prior immunotherapy
  • More than 30 days since prior investigational drugs
  • No prior biological response modifier
  • No concurrent corticosteroids
  • No concurrent immunosuppressive therapy
  • Patient Characteristics:
  • Resident of Orange, San Diego, or Imperial County in California
  • English or Spanish speaking
  • No serious acute or chronic illness
  • Has access to a telephone
  • EXCLUSION CRITERIA
  • Disease Characteristics:
  • Stage IV cervical carcinoma
  • Have undergone previous treatment with a biological response modifier (inferferons, interleukins) or prior immunotherapy within four weeks of study enrollment
  • Used investigational drugs within 30 days of execution of the informed consent
  • Required corticosteroids or were under immune suppression for any reason including an organ allograft or HIV infection
  • Patients with metastatic disease or ongoing treatment
  • Any acute or chronic illness, including autoimmune states, as judged clinically significant by the investigators
  • Patient Characteristics:
  • Non-English or Spanish speakers

Exclusion

    Key Trial Info

    Start Date :

    August 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 30 2007

    Estimated Enrollment :

    36 Patients enrolled

    Trial Details

    Trial ID

    NCT00086242

    Start Date

    August 1 2004

    End Date

    June 30 2007

    Last Update

    March 8 2019

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    UCI, Health Policy and Research Center

    Irvine, California, United States, 92697